Drug intelligence / Profile preview

RMG-G7

Development stage: Preclinical
Lead developer: RxOmeg Therapeutics
Modality: Small Molecules

Overview

RMG-G7 is a reformulated small molecule therapeutic currently in preclinical development by RxOmeg Therapeutics. The program is designed to address high unmet needs in Sjögren's Disease and orphan cardiology indications. RxOmeg's development strategy centers on the innovative reformulation of well-characterized molecules to improve their therapeutic utility in rheumatologic and cardiac inflammatory conditions. As of the current pipeline status, the specific identity of the underlying small molecule and its biological target remain proprietary and undisclosed.

Beyond the preview

Go deeper on RMG-G7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RMG-G7.

Explore the full profile